Literature DB >> 15088775

Original antigenic sin. A confounding issue?

L R Haaheim1.   

Abstract

The 'Doctrine of Original Antigenic Sin', first phrased by Francis, Davenport & Hennessy in 1953, and followed up by occasional papers in the 1960s and 1970s, has lived a life in obscurity and negligence ever since it was postulated. From time to time, and with long intervals, papers on the subject appear. And almost invariably, they are quickly forgotten. Although many will erroneously use the phrase 'Antigenic Sin' to describe classical cross-reactions, the term should be reserved to describe the strain-specific serological response to earlier influenza strains after infection or vaccination with later variants, irrespective of whether one or more antigenic shifts had occurred during the observation period of the study. It is unlikely that antibodies generated under the mechanism of Antigenic Sin will have any major epidemiological relevance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15088775

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  10 in total

1.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Authors:  Grazia Galli; Kathy Hancock; Katja Hoschler; Joshua DeVos; Michaela Praus; Monia Bardelli; Carmine Malzone; Flora Castellino; Chiara Gentile; Teresa McNally; Giuseppe Del Giudice; Angelika Banzhoff; Volker Brauer; Emanuele Montomoli; Maria Zambon; Jacqueline Katz; Karl Nicholson; Iain Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

2.  Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus.

Authors:  Shabnam Alam; Andrea J Sant
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

3.  Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.

Authors:  Christopher D O'Donnell; Amber Wright; Leatrice Vogel; Kobporn Boonnak; John J Treanor; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

Review 4.  The growth and potential of human antiviral monoclonal antibody therapeutics.

Authors:  Wayne A Marasco; Jianhua Sui
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

Review 5.  Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.

Authors:  Michael W Russell; Jiri Mestecky
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

Review 6.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

7.  Comparison of strain-specific antibody responses during primary and secondary infections with respiratory syncytial virus.

Authors:  Paul D Scott; Rachel Ochola; Charles Sande; Mwanajuma Ngama; Emelda A Okiro; Graham F Medley; D James Nokes; Patricia A Cane
Journal:  J Med Virol       Date:  2007-12       Impact factor: 2.327

8.  Characterization of immune responses induced by immunization with the HA DNA vaccines of two antigenically distinctive H5N1 HPAIV isolates.

Authors:  Yulong Gao; Zhiyuan Wen; Ke Dong; Gongxun Zhong; Xiaomei Wang; Zhigao Bu; Hualan Chen; Ling Ye; Chinglai Yang
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

9.  Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination.

Authors:  Upma Gulati; Wendy A Keitel; Gillian M Air
Journal:  Influenza Other Respir Viruses       Date:  2007-07       Impact factor: 4.380

10.  Understanding Primate Herpesviruses.

Authors:  R Eberle; L Jones-Engel
Journal:  J Emerg Dis Virol       Date:  2017-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.